M H Schiff

Summary

Publications

  1. ncbi Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin
    Michael Schiff
    University of Colorado, Denver, CO, USA
    Curr Med Res Opin 25:2471-7. 2009
  2. ncbi Integrated safety in tocilizumab clinical trials
    Michael H Schiff
    Rheumatology Division, University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Arthritis Res Ther 13:R141. 2011
  3. ncbi HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis
    Michael Schiff
    Division of Rheumatology, University of Colorado School of Medicine, Denver, CO, USA
    Expert Rev Gastroenterol Hepatol 6:25-35. 2012
  4. ncbi The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
    M Schiff
    University of Colorado, Greenwood Village, CO 80111, USA
    Ann Rheum Dis 68:1708-14. 2009
  5. ncbi Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis
    Michael Schiff
    University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Clin Rheumatol 29:583-91. 2010
  6. ncbi Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials
    Michael Schiff
    University of Colorado School of Medicine, Greenwood Village, Colorado 80111, USA
    Clin Drug Investig 30:613-24. 2010
  7. ncbi Abatacept treatment for rheumatoid arthritis
    Michael Schiff
    School of Medicine, University of Colorado, Denver, CO, USA
    Rheumatology (Oxford) 50:437-49. 2011
  8. ncbi Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee
    Michael Schiff
    Denver Arthritis Clinic, and University of Colorado, 200 Spruce Street, Suite 100, Denver, CO 80230, USA
    J Rheumatol 31:1373-83. 2004
  9. ncbi A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies
    Michael Schiff
    Denver Arthritis Clinic, Denver, Colorado 80230, USA
    Clin Ther 25:993-1001. 2003
  10. ncbi Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications
    Michael H Schiff
    University of Colorado School of Medicine, Greenwood Village, CO 80111, USA
    Am J Manag Care 16:S243-8. 2010

Detail Information

Publications27

  1. ncbi Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin
    Michael Schiff
    University of Colorado, Denver, CO, USA
    Curr Med Res Opin 25:2471-7. 2009
    ..This study evaluated the platelet inhibitory effects of over-the-counter (OTC) doses of naproxen sodium (NAPSO) compared to that of a prescription dose of NAPSO and to low-dose enteric-coated aspirin (EC-ASA)...
  2. ncbi Integrated safety in tocilizumab clinical trials
    Michael H Schiff
    Rheumatology Division, University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Arthritis Res Ther 13:R141. 2011
    ..Patients from these randomized trials could receive tocilizumab treatment in open-label extension trials. Here, the long-term safety profile of tocilizumab, using pooled data from all of these trials, is reported...
  3. ncbi HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis
    Michael Schiff
    Division of Rheumatology, University of Colorado School of Medicine, Denver, CO, USA
    Expert Rev Gastroenterol Hepatol 6:25-35. 2012
    ....
  4. ncbi The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
    M Schiff
    University of Colorado, Greenwood Village, CO 80111, USA
    Ann Rheum Dis 68:1708-14. 2009
    ..To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout...
  5. ncbi Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis
    Michael Schiff
    University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Clin Rheumatol 29:583-91. 2010
    ..Abatacept could be considered as a first-line biologic DMARD in the treatment of RA...
  6. ncbi Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials
    Michael Schiff
    University of Colorado School of Medicine, Greenwood Village, Colorado 80111, USA
    Clin Drug Investig 30:613-24. 2010
    ..With its proven immunosuppressive effects and favourable toxicity profile, mycophenolate mofetil was postulated as a potential candidate for treating rheumatoid arthritis...
  7. ncbi Abatacept treatment for rheumatoid arthritis
    Michael Schiff
    School of Medicine, University of Colorado, Denver, CO, USA
    Rheumatology (Oxford) 50:437-49. 2011
    ..Furthermore, efficacy data from studies in patients with early disease suggest that the risk-benefit profile of abatacept may be more favourable when introduced earlier in the treatment paradigm...
  8. ncbi Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee
    Michael Schiff
    Denver Arthritis Clinic, and University of Colorado, 200 Spruce Street, Suite 100, Denver, CO 80230, USA
    J Rheumatol 31:1373-83. 2004
    ..To compare the analgesic efficacy and safety of nonprescription doses of naproxen sodium, ibuprofen, and placebo in patients with osteoarthritis (OA) of the knee...
  9. ncbi A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies
    Michael Schiff
    Denver Arthritis Clinic, Denver, Colorado 80230, USA
    Clin Ther 25:993-1001. 2003
    ..Because disease variables are quantified over time, AUC measures summarize the therapeutic effects during the entire course of the trial or treatment course. Trials of RA agents have used AUC-based calculations in data analyses...
  10. ncbi Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications
    Michael H Schiff
    University of Colorado School of Medicine, Greenwood Village, CO 80111, USA
    Am J Manag Care 16:S243-8. 2010
    ..However, further clinical studies are needed to fully evaluate the long-term clinical and economic outcomes of these agents in patients with UA...
  11. ncbi Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
    Michael Schiff
    Department of Rheumatology, University of Colorado, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Ann Rheum Dis 70:2003-7. 2011
    ..To assess the efficacy and safety of abatacept in biological-naive patients with rheumatoid arthritis and an inadequate response to methotrexate treated in the long-term extension (LTE) of the ATTEST trial...
  12. ncbi Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
    M H Schiff
    University of Colorado School of Medicine, Denver, CO, USA
    Semin Arthritis Rheum 30:196-208. 2000
    ..To provide a review of the renal toxicity of disease-modifying antirheumatic drugs (DMARDs) currently used for the treatment of rheumatoid arthritis...
  13. ncbi Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    M Schiff
    Denver Arthritis Clinic, 200 Spruce Street 100, Denver, CO 80230, USA
    Ann Rheum Dis 67:1096-103. 2008
    ..The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197...
  14. ncbi Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
    M H Schiff
    Clinical Research, Denver Arthritis Clinic, 200 Spruce Street, Suite 100, Denver, CO 80230, USA, and Department of Rheumatology, Charite Humboldt University, Berlin, Germany
    Ann Rheum Dis 65:889-94. 2006
    ..To assess the safety of adalimumab in global clinical trials and postmarketing surveillance among patients with rheumatoid arthritis (RA)...
  15. ncbi Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis
    M H Schiff
    Denver Arthritis Clinic, 4545 E 9th Avenue, Suite 510, Denver, CO 80220, USA
    Ann Rheum Dis 59:i103-8. 2000
    ..I1Ra offers a unique selective, targeted mechanism of action to block the IL1 mediated effects of RA...
  16. ncbi Infliximab treatment maintains employability in patients with early rheumatoid arthritis
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:716-22. 2006
    ..However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone...
  17. ncbi Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Stanley Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Arthritis Rheum 46:614-24. 2002
    ..To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA)...
  18. ncbi Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study
    Daniel E Furst
    University of California at Los Angeles Medical School, CA 90024, USA
    Arthritis Rheum 46:2020-8. 2002
    ..To assess the efficacy, safety, and optimal dose of tacrolimus monotherapy in patients with rheumatoid arthritis (RA)...
  19. ncbi Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    E William St Clair
    Duke University Medical Center, Durham, North Carolina, USA
    Arthritis Rheum 50:3432-43. 2004
    ..CONCLUSION: For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment with MTX alone...
  20. ncbi Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study
    Desiree van der Heijde
    Department of Internal Medicine, Division of Rheumatology, University Hospital, Maastricht, The Netherlands
    Arthritis Rheum 52:1205-15. 2005
    ..To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS)...
  21. ncbi Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    Mark C Genovese
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 353:1114-23. 2005
    ....
  22. ncbi A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis
    Daniel E Furst
    Department of Rheumatology, University of California at Los Angeles, California 90095, USA
    J Rheumatol 32:2303-10. 2005
    ..In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA)...
  23. ncbi Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  24. ncbi Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
    Michael Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Ann Rheum Dis 66:228-34. 2007
    ....
  25. ncbi Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:702-10. 2006
    ....
  26. ncbi Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington, USA
    J Rheumatol 32:616-21. 2005
    ..CONCLUSION: Prasterone treatment prevented BMD loss and significantly increased BMD at both the lumbar spine and total hip in female patients with SLE receiving exogenous glucocorticoids...
  27. ncbi Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
    Michelle A Petri
    Department of Medicine, John Hopkins Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 46:1820-9. 2002
    ..5 mg/day for 2 months or longer while maintaining stable or reduced disease activity in steroid-dependent women with systemic lupus erythematosus (SLE)...